Black Diamond joins ArriVent in the PACC pack
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
ESMO 2024 – Regeneron's fianlimab do-over
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ESMO 2024 – Scorpion joins Relay in the alpha club
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
